News

Atezolizumab has received FDA approval for the treatment of patients with metastatic NSCLC who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring <em>EGFR</em> or <em>ALK</em> abnormalities.&nbsp;

Rimas Lukas, MD, discusses the next steps in glioblastoma research, as well as the potential use of IDO inhibitors in the treatment of GBM, and recent studies showing promise in the field.

Optune, a noninvasive device that delivers tumor-treating fields to the brain, provides oncologists, specifically those who treat glioblastoma multiforme, an opportunity to apply technology as part of their standard treatment regimen.

Loretta J. Nastoupil, MD, discusses ongoing lymphoma clinical trials and how practitioners can better identify high- and poor-risk patients with large cell lymphomas.

The positive opinion for the BCL-2 inhibitor has been sent to the European Commission, which usually issues its final approval decision within 2 to 3 months of the CHMP recommendation.

Frontline pembrolizumab was superior to ipilimumab in the treatment of patients with advanced melanoma,&nbsp;a final analysis of the OS data from the KEYNOTE-006 trial showed.

ASCO-CAP recently released new guidelines for the use of FISH testing for HER2 in breast cancer, due to discrepancies in HER2-testing results.

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

Steve Coutre, MD, discusses how he determines which CLL treatment option is best for which patient, the advantage of treating patients with ibrutinib over chemoimmunotherapy, and new oral agents currently being investigated in the space.

Results from the KRISTINE^&nbsp;and NSABP B-41&nbsp;trials provided the latest data on the use of pertuzumab, trastuzumab, ado-trastuzumab emtansine, and lapatinib for the neoadjuvant treatment of patients with HER2-positive breast cancer.

William J. Gradishar, MD, summarizes the need for new strategies to alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.

Elizabeth Plimack, MD, discusses recent pivotal findings in the field of genitourinary malignancies, specifically renal cell carcinoma (RCC) and bladder cancer.

The antibody drug conjugate XMT-1536 could change the treatment paradigm for both non-small cell lung cancer (NSCLC) and ovarian cancer, according to Donald Bergstrom, MD, PhD.

William G. Wierda, MD, PhD,&nbsp;discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.

Emily M. Ko, MD, gives an overview of a study examining risk factors for surgical treatment delay for patients with endometrial cancer.

Treatment with KTE-C19 demonstrated an objective response rate (ORR) of 79% and a complete remission (CR) rate of 52% for patients with aggressive, chemorefractory non-Hodgkin&#39;s lymphoma (NHL).

<em>Targeted Oncology</em> speaks with Shaji Kumar, MD, to understand the roles that the new criteria for response and minimal residual disease (MRD) assessment in multiple myeloma&nbsp;and what role MRD testing will play going forward in multiple myeloma.<br /> &nbsp;

The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.&nbsp;

In a 14-0 vote, the FDA&rsquo;s Oncologic Drugs Advisory Committee (ODAC) denied the approval of apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.

A type II variation application for the use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) who have progressed following platinum-based chemotherapy is now under formal review.

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate (ORR) of 20% when administered to patients with advanced c-MET&ndash;dysregulated non&ndash;small cell lung cancer (NSCLC).

Lori Rink, PhD, speaks about what oncologists have learned about GIST in the past 3 decades, the important role of imatinib mesylate (Gleevec) in treating the disease, and the personalized treatment approach on the horizon.

The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), according to results from an expansion cohort of the phase Ib KEYNOTE-012 trial.

In an interview with <em>Targeted Oncology</em>, Naiyer Rizvi, MD, director of Thoracic Oncology and Immunotherapy at Columbia University Medical Center, discusses data from the&nbsp;phase III KEYNOTE-024 trial and expressed his optimism about immunotherapy in the NSCLC field.

James Hsieh, MD, PhD, discusses the 3 &quot;eras&quot; in the treatment of kidney cancer.

Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma (HCC) both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease, according to experts who debated the relative merits of the techniques at the 2016 International Liver Cancer Association (ILCA) conference.

Michael Choti, MD, discusses the importance of biomarkers when it comes to choosing treatments, which treatments to choose for certain patients with GI cancer, and the improvement of systemic therapy.

According to results from a phase Ib study, pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1&ndash;positive advanced cervical squamous cell cancer.